FDA Clearance Tracker · P210040
RESOLUTION ctDx FIRST
Last checked: Nov 19, 2026Latest source record: Dec 12, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Dec 12, 2022
Approval withdrawn
Time to decision
349 days
Received Dec 28, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P210040
- Device name
- RESOLUTION ctDx FIRST
- Applicant
- Exact Sciences Corporation
- Applicant location
- Madision, WI
- Received
- Dec 28, 2021
- Decided
- Dec 12, 2022
- Decision
- Approval withdrawn
- Supplements
- 1 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the Agilent Resolution ctDx FIRST assay. The device is a qualitative next generation sequencing-based, in vitro diagnostic test that uses targeted hybrid-capture sequencing technology to detect and report single nucleotide variants (SNVs) and deletions in two genes. The Agilent Resolution ctDx FIRST assay utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs). The test is intended as a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who may benefit from treatment with the targeted therapy listed in Table 1, in accordance with the approved therapeutic labeling.Table 1. Companion Diagnostic IndicationIndication: Non-small cell lung cancer (NSCLC); Biomarker: KRAS G12C; Therapy: KRAZATI (adagrasib) A negative result from a plasma specimen does not assure that the patients tumor is negative for genomic findings. Patients with NSCLC who are negative for the biomarker listed in Table 1 should be reflexed to tissue biopsy testing for Table 1 biomarker using an FDA-approved tumor tissue test, if feasible.Additionally, the test is intended to provide tumor mutation profiling for SNVs and deletions in the EGFR gene for use by qualified health care professionals in accordance with professional guidelines in oncology for patients with NSCLC. The test is for use with patients previously diagnosed with NSCLC and in conjunction with other laboratory and clinical findings.Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.The Agilent Resolution ctDx FIRST assay is a single-site assay performed at Resolution Bioscience, Inc.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PQP. The earliest in FDA's data is P160018, decided Dec 19, 2016.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Exact Sciences Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P230043 · Decided Oct 3, 2024 · 286 days after receipt
Device type: System, colorectal neoplasia, DNA methylation and hemoglobin detection (PHP) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.